Pricing Log in Create free account
Friday 6 November 2026 Export SEPN’s income statement to Excel — free account

Septerna, Inc.

SEPN Healthcare Biotechnology

Septerna, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $46.0 million, up 4,174.5% from fiscal 2024.

Revenue
+22,375.6%
EPS
+48.2%
Free cash flow
−9.01%

Quarter to June 2026, against a year earlier

49.54 2.19 +4.63%
Market cap
$2.2B
P/E
0.0×
Fwd P/E
−32.6×
Dividend yield
—
F-score
5/9
Altman Z
3.41
Beneish M
32.85
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Septerna, Inc. (SEPN) EPS (diluted)

Alert me on EPS (diluted)

Septerna, Inc.'s EPS (diluted) for fiscal 2025 was −$1.10, compared with −$7.26 in fiscal 2024. Over the twelve months to 30 June 2026 it was −$0.54. Septerna, Inc. ranks 137th of 580 Biotechnology companies by EPS (diluted).

EPS (diluted), annual

Embed this chart

Annual newest first

Period EPS (diluted) Change
FY2025 −$1.10 —
FY2024 −$7.26 —
FY2023 $0.29 —

Quarterly newest first

Period EPS (diluted) Change
Jun 2026 −$0.29 —
Mar 2026 −$0.19 —
Dec 2025 −$0.24 —
Sep 2025 $0.18 —
7 more quarters

EPS (diluted) against peers

Company EPS (diluted)
AUPH Aurinia Pharmaceuticals Inc compare $2.29
VCEL Vericel Corporation compare $0.65
LKFT Lakefront Biotherapeutics - Sponsored ADR compare −$0.29
SEPN Septerna, Inc. −$0.54
ZYME Zymeworks Inc. compare −$2.02
IMNM Immunome, Inc. compare −$2.53
BHVN Biohaven Ltd. compare −$3.86
PVLA Palvella Therapeutics, Inc. compare −$4.83
VERA Vera Therapeutics, Inc. compare −$5.86

What EPS (diluted) is

Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.

Reported line item

The full definition of EPS (diluted) →

More on SEPN